Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Escalate
Torsades de pointes, seizure, severe tetany or refractory ventricular arrhythmia with low magnesium requires immediate monitored treatment. Hypermagnesaemia with loss of reflexes, hypotension, bradycardia, heart block, respiratory depression or reduced consciousness needs cessation of magnesium, ABCDE support, intravenous calcium under the local emergency protocol and urgent renal or critical-care assessment for clearance.
Synopsis
Recognise bidirectional magnesium toxicity, correct linked calcium and potassium disturbance, and adapt replacement or removal to renal function.
Serum magnesium represents a small extracellular fraction, so a result can underestimate tissue depletion; interpret symptoms, losses and companion electrolytes as well as the number.
Hypomagnesaemia causes neuromuscular irritability, seizure, QT-related ventricular arrhythmia and renal potassium wasting, and it impairs PTH release and action to produce hypocalcaemia.
Common low-magnesium drivers include diarrhoea, malabsorption, alcohol dependence, refeeding, diuretics, proton pump inhibitors, aminoglycosides, cisplatin, calcineurin inhibitors and uncontrolled diabetes.
Key red flags
Low-magnesium irritability
Tremor, fasciculation, cramps, hyperreflexia, carpopedal spasm, nystagmus, confusion or seizure reflects increased neuromuscular excitability and companion calcium disturbance.
Investigation priorities
01
Repeat serum magnesium with renal profileFirst step
Confirm direction and severity and determine whether excretion can support replacement or recovery.
Management branches
LowTreat magnesium depletion by risk
Magnesium is low with symptoms, arrhythmia, linked electrolyte disturbance or an ongoing high-risk cause.
Assess ABCDE, ECG, renal function, potassium and calcium, identify ongoing gastrointestinal or renal losses and stop or modify causal medicines where clinically safe.
Use a locally selected oral preparation for stable mild disease; use monitored intravenous magnesium sulfate when severe symptoms, torsades, seizure or malabsorption makes enteral treatment inappropriate.
Key medicines
Magnesium sulfate for severe deficiencySelect concentration, dose and infusion duration from the current licensed product and local hypomagnesaemia chart according to symptoms, measured magnesium, weight, ongoing loss and renal function; serious arrhythmia uses its dedicated resuscitation protocol.
Oral magnesium preparationChoose the locally formulary-approved licensed salt and divided dose from the BNF or SmPC, titrating to tolerance, serum response and continuing losses rather than converting different salts by tablet count.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.